Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Ethosuximide (compound)

Name: Ethosuximide
PubChem Compound ID: 10630591
Description: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Molecular formula: C7H11NO2
Molecular weight: 141.168 g/mol
Name: Ethosuximide
Name (isomeric): DB00593
Drug Type: small molecule
Description: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Ethosuccinimide; Etosuximida; Ethosuccimide; Aethosuximide; Ethosuxide
Brand: Atysmal, Ronton, Suximal, Zartalin, Simatin, Piknolepsin, Petnidan, Thetamid, Peptinimid, Succimal, Zarodan, Mesentol, Ethymal, Petinimid, Etomal, Epileo Petit Mal, Pyknolepsinum, Thilopemal, Asamid, Pentinimid, Suxinutin, Pemalin, Zarontin, Succimitin, Emeside, Suxin, Capitus, Zarondan, Pemal, Suxilep, Zaraondan
Category: Succinimides, Anticonvulsants
CAS number: 77-67-8
Indication: For the treatment of petit mal epilepsy.
Used in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central...
show more »
Mechanism of Action:
Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The i...
show more »
Absorption: Bioavailability following oral administration is 93%.
Biotransformation: Hepatic, via CYP3A4 and CYP2E1.
Half Life: 53 hours
Toxicity: Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.
Affected organisms: Humans and other mammals
Food interaction:
Avoid alcohol.
Take with food.
Drug interaction:
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed.
TriprolidineThe CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
TelithromycinTelithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed.